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Supplemental Material 
 
 
SCIENTIFIC MEMBERS OF THE CONSORTIUM 
 
See Table S1. 
 
 
DATA 
 
Examinations 
Examinations were performed in the morning after a 10-hour overnight fast. Participants remained on their usual non-
antidiabetic medications; metformin, if used, was stopped for the 24 hours preceding the study visit and restarted 
immediately after. Anthropometric data, blood pressure, and urine samples were collected. An intravenous cannula was 
inserted into a forearm vein according to local protocols. Baseline blood samples were immediately collected for 
analysis of glutamic acid decarboxylase and islet antigen-2 antibodies, glucagon-like peptide-1, glucagon, insulin, C-
peptide, HbA1c, and DNA.  
 
Mixed-meal tolerance test (MMTT) 
Before the MMTT, fasting samples for glucose, insulin and C-peptide analysis were collected. The MMTT consisted of 
a 250 ml Fortisip liquid drink (18.4 g carbohydrate per 100 ml) over a period of 2–5 min. Blood samples were collected 
every 30 min for two hours for subsequent glucose, insulin and C-peptide assays. 
 
Biochemistry assays 
Measurements were performed by a central laboratory. Plasma glucose was measured by the enzymatic colorimetric 
assay GOD-PAP, using Roche MODULAR P analyzers (Hoffmann-La Roche, Basel, Switzerland). Plasma insulin and 
C-peptide were measured by electrochemiluminescence, using Roche E170 analyzers (Hoffmann-La Roche). HbA1c 
was measured by ion-exchange high-performance liquid chromatography, using Tosoh G8 analyzers (Tosoh 
Bioscience, San Francisco, CA, USA). 
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured by UV absorbance without 
pyridoxal phosphate activation. Gamma-glutamyl transferase (GGT) was measured by enzymatic colorimetric assay. 
Serum creatinine and albumin were measured with the Creatinine Jaffé method and the bromocresol green method, 
respectively. Cholesterol was measured by enzymatic colorimetric methods, HDL-cholesterol was measured directly 
using PEG-modified enzymes and dextran sulphate, triacylglycerol was measured by quantitative determination with 
glycerol blanking. AST, ALT, GGT, serum creatinine and albumin, cholesterol, HDL-cholesterol and triacylglycerol 
were measured using a Roche MODULAR P analyzer (Roche Diagnostics, Indianapolis, IN, USA). LDL-cholesterol 
was calculated from the Friedewald formula. 
Intact proinsulin was measured using the TECO Medical Intact Proinsulin ELISA kit in use on the Dynex DS2 analyzer. 
Glucagon, glutamic acid decarboxylase (GAD) and islet antigen-2 antibodies (IA-2) were measured using a DS2 Elisa 
robot, Dynex technologies. 
Plasma samples for glucagon-like peptide-1 (GLP-1) measurement were collected in P800 tubes (Becton Dickinson, 
Wokingham, UK) to prevent intrinsic proteolysis. Intact GLP-1 was measured using MSD GLP-1 active kit (product 
code K150JWC; Meso Scale Diagnostics, Rockville, MD, USA). Total GLP-1 was assayed using MSD GLP-1 total kit 
(product code K150JVC; Meso Scale Diagnostics). 
Each biochemical assay was performed using validated standard methods. Reference samples were included in all 
procedures to control for inter-assay variation, and the laboratory regularly participated in international external quality 
assessment schemes. 
Body composition 
Body mass index (BMI) was calculated as weight divided by height squared, and waist circumference was measured at 
the level of the umbilicus at mid-respiration. The hepatic steatosis index (HSI) was calculated as described previously 
(1). 
 
Abdominal MRI 
The volume of adipose tissue was measured using MRI, as described elsewhere (2). Total abdominal adipose tissue was 
separated into intra-abdominal adipose tissue, also referred to as “visceral” fat, and abdominal subcutaneous adipose 
tissue. Liver and pancreas fat and iron were derived simultaneously using a multiecho MRI technique (2–4). 
 
Dietary data  
Self-reported dietary intake was assessed by 24-hour multi-pass method, using food habit and 24-hour recall 
questionnaires. Nutritional analysis was undertaken using Dietplan-7 software (Forestfield Software Ltd, Horsham, 
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UK). All diet coders were trained by a lead research dietician/nutritionist using a study specific operational manual 
protocol. Detailed description of the coding and diet analysis protocol are reported elsewhere (5).   
Dietary patterns were assessed in concordance with the WHO dietary guidelines using the validated “Healthy Diet 
Indicator” (HDI) (6); a higher HDI score indicates a more favorable diet. The score was calculated from the dietary 
intakes of all food and drink consumed except alcohol, which was analyzed separately. 
 
Physical activity intensity and sedentary behaviour 
Participants were fitted with a wrist-worn triaxial accelerometer (ActiGraph GT3X+; Actigraph LLC, Pensacola, FL, 
USA) for measurement of physical activity, sedentary behavior and sleep over 10 days. The monitor was fitted to the 
participant’s non-dominant wrist using an adjustable strap. The participant was requested to wear the monitor 
continuously for 10 days to allow habitual uninterrupted measures of both sleep and physical activity. The monitor was 
set to record at 30 Hz with the manufacturer’s sleep mode disabled. High-pass-filtered vector magnitude (hpfVM) was 
derived as described elsewhere (7). In this analysis, we used the 10-day mean hpfVM and the percentage of hpfVM 
values ≤ 48 mg as measures of physical activity intensity and sedentary behavior. 
 
Type 2 diabetes (T2D) polygenic risk score 
A T2D polygenic risk score was computed from the 403 single-nucleotide polymorphisms (SNPs) and the respective 
effect sizes reported for T2D in Mahajan et al. (8). The individual score values were obtained by summing up the 
number of risk alleles at each locus multiplied by its effect size. 
 
Additional questionnaires 
Questionnaire data were collected on alcohol consumption, smoke habits, family history of diabetes and medication 
history. 
 
The whole set of traits considered in this study is reported in Table S2. 
 
 
METHODS 
 
Area under the curves and mean values 
Areas under the curve (AUC) of several MMTT variables were computed according to the trapezoidal rule and mean 
values as AUC/time interval. 
 
Mathematical modelling of β-cell function 
From MMTT glucose and C-peptide, the following β-cell function parameters were calculated by mathematical 
modelling (9): glucose sensitivity (GS), i.e., the slope of the relationship between glucose concentration and insulin 
secretion rate; rate sensitivity (RS), marker of early insulin release; insulin secretion rate at 8 mmol/l glucose (ISRstd); 
potentiation factor ratio (PR), the ratio between the potentiation factor at 2- and 0-hours, ; total insulin secretion 
(ISRtot), i.e., the AUC of insulin secretion during the whole MMTT. Insulin secretion rate was calculated from C-
peptide using Van Cauter’s C-peptide model (10). 
 
Insulin clearance 
Fasting insulin clearance (CLIb) was calculated as the ratio between fasting insulin secretion and fasting insulin 
concentration. The MMTT insulin clearance (CLIm) was calculated as the ratio of the AUCs of insulin secretion and 
insulin concentration during the MMTT.  
 
Mathematical modelling of HbA1c progression rate 
The HbA1c trajectories were described with a conditional linear mixed-effect model (11). The conditional approach 
employs a linear transformation of the data to derive a longitudinal and a cross-sectional component, which are 
orthogonal. The transformation makes modelling of the longitudinal component independent of the cross-sectional 
effects: the former is relevant for quantification of HbA1c progression rate, while the latter are potential confounders 
that need not to be considered in the conditional approach. In particular, the approach eliminates possible spurious 
correlations between the longitudinal parameters and baseline HbA1c, which may arise if baseline HbA1c is not 
accurately modelled. 
The longitudinal HbA1c component was described as the sum of the following terms:  
• a proportional effect of time, described by the parameter ri, where i represents a specific individual, 
represented as a random variable with a normal distribution; 
• a proportional effect of BMI; 
• a linear effect of the metformin dose, expressed as percentage of a maximal dose of 3 grams; 
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• a linear effect of the cumulative dose for the other antidiabetic drugs (insulin excluded), expressed as sum of 
the percentages of the maximum dose of each drug; 
• a constant effect of insulin treatment; 
• a proportional effect of delay in HbA1c assay, i.e. of the difference between the time of measurement and the 
time of sample collection; 
• a residual error εik, where k refers to the time point, represented as a random variable from a normal 
distribution with zero mean. 
The insulin and BMI effects were constrained to be negative and positive, respectively. The linear effects of the 
treatment dose were modelled as 0 for dose=0, and as a+b∙dose for dose>0, where a and b were different for metformin 
and the other antidiabetic drugs and were constrained to be negative. Maximum doses for antidiabetic drugs different 
from metformin and insulin were fixed to the values in Table S3. A medication was considered effective at a given time 
if it was taken at least 30 days before. 
The ri parameter represents the HbA1c underlying progression rate, adjusted for changes in BMI and antidiabetic 
treatments. 
The model parameters were estimated using Monolix 2016 R1(12), which implements the SAEM algorithm for 
estimation of mixed-effect models. In a first step, the software identifies mean and standard deviation of the population 
distribution of the model parameters with inter-individual variability (in our case just r). In the second step, the software 
computes the individual estimates of the parameters (in our case ri) by simultaneously fitting the data and using the 
previously estimated distributions as priors (maximum a posteriori estimation). 
The parameter estimates of the HbA1c progression model are reported in Table S4. The BMI and treatment effects were 
concordant with what shown in the literature(13), considering the low baseline HbA1c values in this study (6.41±0.53 %, 
46.5±5.8 mmol/mol, mean ± standard deviation). 
 
Progression rates for other traits 
The progression rates for all other traits were derived in the same way as for HbA1c, but without including the effect of 
treatments and assay delay. The BMI effect was included only in the models for OGIS and QUICKI. The BMI effects 
on OGIS and QUICKI progression rates were -8.68±11% (estimate±relative standard error) ml min-1 kg-1 and -
0.00157±9% m2 kg-1, respectively. 
 
On the multivariable analyses 
Baseline values of the β-cell function parameters of some subjects were discarded due to high uncertainty in their 
estimates. 
 
 
RESULTS 
 
Progression rates of HbA1c and other traits 
HbA1c was measured at two visits in 6% of participants, at three visits in 15% of participants, at four visits in 75% of 
participants, and at five visits in 4% of participants. 
In 50% of the subjects, T2D was managed via lifestyle only along the whole study.  
The estimates of the progression rates for HbA1c, adjusted for changes in BMI and in diabetes medications, and for the 
other traits are reported in Figure S1 (histogram for HbA1c progression rates only) and Table S5. 
 
Variables associated with HbA1c progression rate 
The pairwise associations between HbA1c progression rate and baseline values and progression rates of the investigated 
traits are shown in Figure S2. 
The standardized coefficients and the p values of the independent variables included in the multivariable linear analysis 
of HbA1c progression rate are shown in Table S6. The table presents different regression models, all adjusted for sex, 
baseline age and center, and considering different subsets of subjects, based on the availability of different subsets of 
variables. The models described  include those with a unique independent variable (models named “-1”), a model with 
the adjustment variables only (model “0”), and models including or excluding the effects of baseline liver fat or visceral 
fat, and the effects of baseline BMI and fasting HDL-cholesterol, found to have non-significant effects once visceral or 
liver fat is included in the analysis. The models presented in the main text are numbered “1” and “9”. 
In the multivariable linear analysis, the indices of insulin sensitivity OGIS and QUICKI, as well as HOMA-IR (14), 
Stumvoll (15) and Matsuda (16) indices (data not shown), were interchangeable in terms of overall analysis results, with 
OGIS producing the best performance (adjusted R2 0.38 vs 0.33, 0.37, 0.28 and 0.29, respectively; N = 625). 
 
Variables associated with fast vs average HbA1c progression 
The logistic analysis reported in the main text defines fast vs average progressors based on a threshold on HbA1c 
progression rate that clearly separate the two groups (0.255 %/year, 2.79 mmol mol-1 year-1, Figure S1). We found that 
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this threshold corresponds to (q50 - q1) + q50, where q1 and q50 are the 1st and 50th quantiles of the distribution of 
individual HbA1c progression rates. The use of lower thresholds allows the identification of larger sets of fast 
progressors. In particular, using the 2nd, 5th or 10th quantile instead of the 1st quantile in the formula, thresholds of 0.200, 
0.143 or 0.121 %/year (2.19, 1.56 or 1.32 mmol mol-1 year-1), respectively, are obtained, with a corresponding number 
of fast progressors of  N=61, N=110 or N=131 subjects, respectively, instead of N=33 (Figure S1). 
With the lower thresholds, discrimination capacity, sensitivity, specificity and accuracy of the logistic model described 
in the main text remain very similar (Figure S3). The effects of the independent variables of the logistic model are also 
essentially unaffected (Figure S3). In all cases, it appears that stronger deterioration and a lower baseline value of OGIS 
and GS, and CLIm increase are independently associated with fast progression. Minor differences are the following: the 
effect of HDL reduction is significant with all thresholds apart from 0.200 %/year; the effect of baseline HDL is 
significant only using thresholds 0.143 and 0.121 %/year; the effect of baseline CLIm is significant only with the lowest 
threshold (0.121 %/year); the effect of baseline HbA1c is significant with all lower thresholds but not with the original 
one. 
The percentage of patients without diabetes medications along the whole study was higher in average than in fast 
progressors (51% vs 30%, p=0.021 from two-sided Chi-square test with α=0.05). At baseline, the percentages of fast 
progressors and of average progressors treated with metformin were not different: 39.4% [24.7-56.3%, 95% CI] vs 
33.9% [30.5-37.5%], respectively (p = 0.64). At the last visit, the percentage of fast progressors treated with any 
diabetes medication, 66.7% [49.6-80.2%], was somewhat higher than the percentage of average progressors treated with 
any diabetes medication, 47.5% [43.8-51.2%] (p = 0.048). This difference was driven by a larger use of diabetes 
medications other than metformin or insulin in fast progressors (30.3% [17.4-47.3%] vs 5.0% [3.6-6.9%], p = 3E-
8). Again at the last visit, the number of patients treated with insulin (seven average progressors) was too low to derive 
any trustworthy comparison between percentages of fast and average progressors treated with insulin (0.0% [0.0-10.4%] 
and 1.0% [0.5-2.1%], respectively, p = 0.74). 
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Copenhagen, Denmark 
Anubha 
 
Mahajan Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom 
Andrea 
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Table S2. Subjects’ baseline traits. 
Trait Abbreviation Baseline value* N 
Age (years) age 62±8 732 
Sex (males) - 58 732 
Body mass index (kg/m2) BMI 30.4±4.9 732 
Waist circumference (cm) waist 103±13 727 
Systolic blood pressure (mm Hg) BPsys 131±16 621 
Diastolic blood pressure (mm Hg) BPdia 75±10 621 
Type 2 diabetes family history - 39 682 
On metformin† - 34 732 
Metformin dosage for subjects on metformin (g)† - 1.0±0.5 732 
HbA1c (%, mmol/mol) HbA1c 6.41±0.53, 46.5±5.8 728 
Fasting glucose (mmol/l)† gb 7.1±1.4 731 
Fasting insulin (pmol/l)† ib 106±69 730 
Mean MMTT glucose (mmol/l)† gm 9.3±2.1 730 
Mean MMTT insulin (pmol/l)† im 459±279 730 
Fasting insulin secretion (pmol min-1 m-2)† ISRb 136±48 730 
Total MMTT insulin secretion (nmol/m2)† ISRtot 44±15 730 
Fasting triacylglycerol (mmol/l) TG 1.51±0.78 732 
Fasting total cholesterol (mmol/l) CHO 4.22±1.15 732 
Fasting LDL-cholesterol (mmol/l) LDL 2.34±0.95 727 
Fasting HDL-cholesterol (mmol/l) HDL 1.18±0.39 732 
Aspartate aminotransferase (U/l) AST 25.6±11.1 732 
Alanine aminotransferase (U/l) ALT 26.2±13.8 732 
AST/ALT ratio (unitless) AST/ALT 1.09±0.48 732 
Gamma-glutamyl transferase (U/l) GGT 51±71 732 
Serum creatinine (µmol/l) SCr 74.7±17.9 732 
Serum albumin (g/l)  ALB 39.7±2.6 165 
Fasting intact glucagon-like peptide-1 (pg/ml) iGLP1 0.64±0.91 725 
Fasting total glucagon-like peptide-1 (pg/ml) tGLP1 9.5±9.3 724 
1-h total glucagon-like peptide-1 (pg/ml) tGLP1.60 19±16 722 
Fasting glucagon (pg/ml) GLG 111±52 704 
1-h glucagon (pg/ml) GLG.60 107±39 717 
2-h glucagon (pg/ml) GLG.120 103±25 184 
1-h GLP-1 increment (pg/ml) GLP1inc.60 9.8±12.7 718 
1-h glucagon increment (pg/ml) GLGinc.60 -3±52 693 
2-h glucagon increment (pg/ml) GLGinc.120 -6±33 183 
1-h intact proinsulin (pmol/l) proins.60 22±14 359 
1-h intact proinsulin to insulin ratio (unitless) proins/ins.60 0.05±0.04 358 
Insulin sensitivity (ml min-1 m-2) OGIS 300±74 728 
Fasting insulin sensitivity (unitless) QUICKI 0.136±0.014 730 
β-cell glucose sensitivity (pmol min-1 m-2 mmol-1 l ) GS 85±56 714 
β-cell rate sensitivity (pmol m-2 mmol-1 l) RS 1138±1102 714 
Insulin secretion rate at 8 mmol/l glucose (pmol min-1 m-2) ISRstd 228±135 714 
Potentiation factor ratio (unitless) PR 1.4±0.6 713 
Fasting insulin clearance (l min-1 m-2) CLIb 1.60±1.02 730 
MMTT insulin clearance (l min-1 m-2) CLIm 0.93±0.30 730 
Hepatic steatosis index (unitless) HSI 41.5±5.9 730 
Fatty liver index (unitless) FLI 67±27 725 
Type 2 diabetes polygenic risk score (unitless) PRS 25.2±0.7 732 
Liver fat (%) liver fat 9±7 480 
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Trait Abbreviation Baseline value* N 
Liver iron content (mg/g tissue) liver iron 1.6±0.5 486 
Pancreas fat (%) pancreas fat 12±8 488 
Pancreas iron content (mg/g tissue) pancreas iron 1.4±0.5 509 
Intra-abdominal adipose tissue (l) visceral fat 5.5±2.2 429 
Abdominal subcutaneous adipose tissue (l) subcutaneous fat 8.0±3.7 429 
Physical activity intensity (mg) PA 35±10 674 
Sedentary behavior (% of time) SED 83±4 674 
Smoking habits (%, current, ex, never) - 13, 50, 37 732 
Average alcohol consumption (%, regularly, occasionally, never) - 58, 25, 17 732 
24-h energy intake (kcal) - 1828±625 644 
24-h protein intake (g) - 89±35 644 
24-h fat intake (g) - 73±34 644 
24-h saturated fat intake (g) - 26±14 644 
24-h added sugars intake (g) - 65±40 644 
24-h carbohydrate intake (g) - 221±91 644 
24-h energy intake-adjusted non‐starch polysaccharides (g/kcal) - 8.7±3.3 644 
24-h energy intake-adjusted fruit & vegetables (g/kcal) - 227±145 644 
24-h energy intake-adjusted wholegrains (g/kcal) - 26±22 644 
24-h energy intake-adjusted fish (g/kcal) - 20±39 644 
24-h energy intake-adjusted red meat (g/kcal) - 46±49 644 
24-h percentage of total energy intake from protein (%) - 20±6 644 
24-h percentage of total energy intake from fat (%) - 36±9 644 
24-h percentage of total energy intake from saturated fat (%) - 13±5 644 
24-h percentage of total energy intake from added sugars (%) - 19±8 644 
24-h percentage of total energy intake from carbohydrate (%) - 49±11 644 
Healthy diet indicator HDI 4.7±2.6 644 
Healthy diet indicator quartiles (% in quartiles 1, 2, 3 and 4) - 23, 25, 26, 26 644 
* Data are mean ± standard deviation of the inter-individual distribution, or percentage. 
† Trait not included in the stepwise multivariable analyses. 
MMTT: mixed meal test. 
 
 
Table S3. Maximum doses for antidiabetic drugs different from insulin. 
Drug Max Dose (mg) Weekly (W) or Daily (D) 
Acarbose 600 D 
Metformin 3000 D 
Dapagliflozin 10 D 
Empagliflozin 25 D 
Alogliptin 25 D 
Sitagliptin 100 D 
Dulaglutide 1.5 W 
Liraglutide 1.8 D 
Gliclazide 320 D 
Glimepiride 4 D 
Glipizide 20 D 
Tolbutamide 2000 D 
 
 
Table S4. Parameter estimates of the HbA1c progression model. 
Parameter Estimate RSE (%) 
r (%/year, mmol mol-1 year-1) 0.0627, 0.685* 17 
BMI effect (% kg-1 m-2, mmol mol-1 kg-1 m-2) 0.131, 1.43 8 
Metformin effect: a (%, mmol/mol) -0.0942, -1.03 74 
Metformin effect: b (%, mmol/mol) -0.00145, -0.0159 101 
Metformin effect with 100% dose (%, mmol/mol) -0.240, -2.62 - 
Other antidiabetic treatment effect: a (%, mmol/mol) -0.0970, -1.06 153 
Other antidiabetic treatment effect: b (%, mmol/mol) -0.00161, -0.0176 138 
Other antidiabetic treatment effect with 100% dose (%, mmol/mol) -0.258, -2.82 - 
Insulin effect (%, mmol/mol) -0.0970, -1.06 205 
Assay delay effect (%/day, mmol mol-1 day-1) -0.00047, -0.00516 19 
RSE: relative standard error of the estimate. 
* Mean value of the population distribution. 
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Table S5. Estimates of the progression rates of the investigated traits. 
Trait Abbreviation Progression rate* 95% CI 
Relative 
progression 
rate† 
N 
Body mass index (kg m-2 year-1) BMI -0.0089±0.52 -0.058,0.040 -0.03 732 
Waist circumference (cm year-1) waist 0.54±1.3 0.37,0.71 0.52 719 
HbA1c (%/year, mmol mol-1 year-1) HbA1c 
0.063±0.18, 
0.69±2.0 
0.041,0.085, 
0.45,0.93 
0.98, 
1.47 732 
Total MMTT insulin secretion (nmol m-2 year-1)‡ ISRtot 0.44±2.4 0.13,0.75 1.00 653 
Fasting triacylglycerol (mmol l-1 year-1) TG 0.038±0.14 0.016,0.060 2.50 719 
Fasting total cholesterol (mmol l-1 year-1) CHO -0.012±0.22 -0.039,0.015 -0.28 719 
Fasting LDL-cholesterol (mmol l-1 year-1) LDL -0.046±0.18 -0.070,-0.023 -1.94 713 
Fasting HDL-cholesterol (mmol l-1 year-1) HDL 0.016±0.040 0.009,0.023 1.36 719 
Aspartate aminotransferase (U l-1 year-1) AST 1.2±3.6 0.77,1.63 4.77 719 
Alanine aminotransferase (U l-1 year-1) ALT 0.53±10 -0.39,1.45 2.01 719 
AST/ALT ratio (year-1) AST/ALT 0.039±0.04 0.024,0.054 3.61 719 
Serum creatinine (µmol l-1 year-1) SCr -0.21±1.2 -0.58,0.16 -0.29 719 
Insulin sensitivity (ml min-1 m-2 year-1) OGIS -8.5±19 -10.7,-6.3 -2.82 649 
Fasting insulin sensitivity (year-1) QUICKI -0.0013±0.0025 -0.0016,-0.0010 -0.95 653 
β-cell glucose sensitivity (pmol min-1 m-2 mmol-1 l 
year-1) GS -1.9±5.0 -3.4,-0.4 -2.19 653 
β-cell rate sensitivity (pmol m-2 mmol-1 l year-1) RS -22±98 -57,13 -1.91 653 
Insulin secretion rate at 8 mmol/l glucose (pmol 
min-1 m-2 year-1) ISRstd -5.2±19 -8.5,-1.9 -2.29 653 
Potentiation factor ratio (year-1) PR -0.0035±0.11 -0.023,0.016 -0.25 652 
Fasting insulin clearance (l min-1 m-2 year-1) CLIb -0.039±0.34 -0.070,-0.008 -2.46 653 
MMTT insulin clearance (l min-1 m-2 year-1) CLIm -0.00069±0.046 -0.0072,0.0058 -0.07 653 
Hepatic steatosis index (year-1) HSI -0.31±0.68 -0.40,-0.22 -0.74 717 
* Data are mean ± standard deviation of the inter-individual distribution, and are expressed as units/year (e.g. %/year or 
mmol mol-1 year-1 for HbA1c). 
† Ratio between mean progression rate and mean baseline value (from Table S2), as percentage per year.  
‡ Progression rate not included in the stepwise multivariable analyses. 
CI: confidence interval on the estimate of the mean; MMTT: mixed meal test. 
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Table S6. Standardized coefficients (with p values as superscripts) and adjusted R2 from multivariable linear analysis of HbA1c progression rate. 
Model Sex Age bas OGIS progr 
CLIm 
progr GS progr TG progr 
HDL 
progr RS progr OGIS bas CLIm bas HbA1c bas GS bas BMI bas HDL bas 
Visceral 
fat bas 
Liver fat 
bas 
Adjusted 
R2 N 
-1 - - -0.24*** 0.16*** -0.23*** 0.25*** -0.11** -0.070.07 -0.11** -0.11** 0.020.58 -0.060.13 0.15*** -0.18*** 0.27*** 0.19*** - 625* 
0 -0.040.61 -0.15*** - - - - - - - - - - - - - - 0.04 625 
1 0.120.08 -0.030.31 -0.57*** 0.28*** -0.25*** 0.15*** -0.14*** -0.09* -0.52*** 0.21*** -0.20*** -0.14*** 0.10** -0.10* - - 0.38 625 
2 0.21* -0.08* -0.61*** -0.08* -0.27*** 0.30*** -0.11* 0.13** -0.53*** 0.22*** -0.22*** -0.15** 0.090.07 -0.050.37 - - 0.40 
407 
(liver fat bas 
available) 
3 0.150.10 -0.060.16 -0.60*** -0.12** -0.28*** 0.25*** -0.14** 0.17*** -0.57*** 0.22*** -0.20*** -0.17** 0.060.24 -0.110.05 - - 0.40 
373 
(visceral fat bas 
available) 
4 0.18* -0.080.06 -0.59*** -0.08* -0.28*** 0.30*** -0.11* 0.13** -0.49*** 0.24*** -0.24*** -0.16** 0.080.10 -0.030.51 - 0.10* 0.40 407 
5 0.25* -0.080.06 -0.58*** -0.12** -0.27*** 0.24*** -0.13** 0.17*** -0.55*** 0.24*** -0.21*** -0.16** 0.010.87 -0.110.06 0.14* - 0.41 373 
6 0.140.14 -0.080.7 -0.63*** 0.25*** -0.26*** 0.17*** -0.10* -0.10* -0.54*** 0.21*** -0.21*** -0.16** - - - 0.12* 0.40 
320 (both visceral 
fat bas and liver fat 
bas available) 
7 0.26** -0.11* -0.63*** 0.25*** -0.25*** 0.16*** -0.080.10 -0.11* -0.56*** 0.23*** -0.20*** -0.14* - - 0.16** - 0.41 
320 (both visceral 
fat bas and liver fat 
bas available) 
8 0.17* -0.09* -0.61*** 0.30*** -0.27*** 0.13** -0.10* -0.080.06 -0.50*** 0.19*** -0.23*** -0.16** - - - 0.11* 0.40 408 
9 0.19* -0.09* -0.62*** 0.24*** -0.16** 0.18*** -0.10* -0.12** -0.56*** 0.21*** -0.20*** -0.16** - - 0.15** - 0.40 374 
Model (-1): HbA1c progression rate = sex + age bas + center + variable (each column represents a specific model, and the various models are given in a unique row for sake of 
clarity). 
Model (0): HbA1c progression rate = sex + age bas + center. 
Model (1): HbA1c progression rate = sex + age bas + center + OGIS progr + CLIm progr + GS progr + TG progr + HDL progr + RS progr + OGIS bas + CLIm bas + HbA1c bas + 
GS bas + BMI bas + HDL bas. This is the model in Figure 1, panel A. 
Model (2): Model (1), with different N (see last column). 
Model (3): Model (1), with different N (see last column). 
Model (4): Model (1) + liver fat bas. 
Model (5): Model (1) + visceral fat bas. 
Model (6): HbA1c progression rate = Sex + Age bas + center + OGIS progr + CLIm progr + GS progr + TG progr + HDL progr + RS progr + OGIS bas + CLIm bas + HbA1c bas 
+ GS bas + liver fat bas. 
Model (7): HbA1c progression rate = Sex + Age bas + center + OGIS progr + CLIm progr + GS progr + TG progr + HDL progr + RS progr + OGIS bas + CLIm bas + HbA1c bas 
+ GS bas + visceral fat bas. 
Model (8): Model (6), with different N (see last column). 
Model (9): Model (7), with different N (see last column). This is the model in Figure 1, panel B. 
* N = 320 for columns Visceral fat bas and Liver fat bas. 
OGIS: insulin sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell glucose sensitivity; TG: fasting triacylglycerol; HDL: fasting HDL-cholesterol; RS: β-cell rate 
sensitivity; BMI: body mass index; progr: progression rate; bas: baseline value; *: p<0.05; **: p<0.01; ***: p<0.001.
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Figure S1. Distribution of the estimated individual progression rates of HbA1c (N=732), adjusted for changes in BMI 
and anti-diabetic medications. Panel A: histogram. Panel B: quantile-quantile plot. In both panels, four straight solid 
lines show four different thresholds used to split subjects into average and fast progressors. The thresholds were 
computed as (q50 – qn) + q50, where qn and q50 are the nth and 50th quantiles of the distribution: the threshold used in the 
main text (n=1) is shown in red, three less conservative thresholds (n=2, 5 and 10) are shown in green, light blue and 
purple, respectively.  
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Figure S2. Pairwise correlation matrixes of the variables considered in this study (diet variables excluded as none was 
associated with HbA1c progression rate). Panel A: pairwise correlations among baseline values of the traits and HbA1c 
progression rates. Panel B: pairwise correlations among all the estimated progression rates. Correlations with HbA1c 
progression rates are displayed in the first columns of both panels. Fill color represents Spearman correlation 
coefficient, where positivity is denoted by red fill, negativity by blue fill, and magnitude by color intensity (see color 
bars) and by elliptic shape. BMI: body mass index; BPsys: systolic blood pressure; BPdia: diastolic blood pressure; gb: 
fasting glucose; ib: fasting insulin; gm: mean mixed meal test (MMTT) glucose; im: mean MMTT insulin; ISRb: fasting 
insulin secretion (ISR); ISRtot: total MMTT insulin secretion; TG: fasting triacylglycerol; CHO: fasting total 
cholesterol; LDL: fasting LDL-cholesterol; HDL: fasting HDL-cholesterol; AST: aspartate aminotransferase; ALT: 
alanine aminotransferase; AST/ALT: AST/ALT ratio; GGT: gamma-glutamyl transferase; SCr: serum creatinine; ALB: 
serum albumin; iGLP1: fasting intact glucagon-like peptide-1 (GLP-1); tGLP1: fasting total GLP-1; tGLP1.60: 1-h total 
GLP-1; GLG: fasting glucagon; GLG.60: 1-h glucagon; GLG.120: 2-h glucagon; GLP1inc.60: 1-h GLP-1 increment; 
GLGinc.60: 1-h glucagon increment; GLGinc.120: 2-h glucagon increment; proins.60: 1-h intact proinsulin; 
proins/ins.60: 1-h intact proinsulin to insulin ratio; OGIS insulin sensitivity; QUICKI: fasting insulin sensitivity; GS: β-
cell glucose sensitivity; RS: β-cell rate sensitivity; ISRstd: insulin secretion rate at 8 mmol/l glucose; PR: potentiation 
factor ratio; CLIb: fasting insulin clearance; CLIm: MMTT insulin clearance; HSI: hepatic steatosis index; FLI: fatty 
liver index; PRS: polygenic risk score; PA: physical activity intensity; SED: sedentary behavior; progr: progression 
rate; *: p<0.05; **: p<0.01; ***: p<0.001.  
  
16 
 
 
Figure S3. Odds ratios ± 95% confidence interval (CI) from the multivariable logistic analysis of fast vs average HbA1c 
progressors, using different thresholds between the two groups. The independent variables are those identified by 
multivariable linear analysis of HbA1c progression, excluding MRI variables (N=625). Panels A to D refer to 
progressively lower thresholds as shown in Figure S1 and in the summary table at the bottom. Age and HDL were log-
transformed. Values for sensitivity, specificity and accuracy were derived via maximization of balanced accuracy. 
OGIS: insulin sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell glucose sensitivity; TG: fasting 
triacylglycerol; HDL: fasting HDL-cholesterol; RS: β-cell rate sensitivity; BMI: body mass index; progr: progression 
rate; bas: baseline value; AUROC: area under the receiver operating curve; *: p<0.05; **: p<0.01; ***: p<0.001.  
